- Home
- Products
- Customized FluoroAb™
- ERBB3
- Seribantumab-iFluor 568
Seribantumab-iFluor 568 (CAT#: ADC-FL-1411)
This product is comprised of an anti-ERBB3 monoclonal antibody (Seribantumab) labeled with iFluor 568. iFluor 568 is a orange-fluorescent dye and it's excitation/emission is 578/603 nm.
- TARGET
- ANTIBODY
- DYE
- Name
- ERBB3
- Alternative Names
- ERBB3; v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian); LCCS2, lethal congenital contracture syndrome 2; receptor tyrosine-protein kinase erbB-3; HER3; proto-oncogene-like protein c-ErbB-3; tyrosine kinase-type cell surface receptor HER3; LCCS2; ErbB-3; c-erbB3; erbB3-S; MDA-BF-1; c-erbB-3; p180-ErbB3; p45-sErbB3; p85-sErbB3; MGC88033;
- Overview
- This gene encodes a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases. This membrane-bound protein has a neuregulin binding domain but not an active kinase domain. It therefore can bind this ligand but not convey the signal into the cell through protein phosphorylation. However, it does form heterodimers with other EGF receptor family members which do have kinase activity. Heterodimerization leads to the activation of pathways which lead to cell proliferation or differentiation. Amplification of this gene and/or overexpression of its protein have been reported in numerous cancers, including prostate, bladder, and breast tumors. Alternate transcriptional splice variants encoding different isoforms have been characterized. One isoform lacks the intermembrane region and is secreted outside the cell. This form acts to modulate the activity of the membrane-bound form. Additional splice variants have also been reported, but they have not been thoroughly characterized.
- Overview
- Humanized Anti-ERBB3 IgG2-lambda antibody, Seribantumab
- Generic name
- Seribantumab
- Species Reactivity
- Human
- Name
- iFluor 568
- Color
- Orange
- Excitation⁄Emission (nm)
- 578/603
- Detection method
- Fluorescent
For Research Use Only. NOT FOR CLINICAL USE.
Related Products
- Anti-RSV MAb (Clone 7)-iFluor® 350 Succinimidyl Ester (CAT#: WJY0-LS1573)
- Anti-FcRL5 MAb (Clone 2)-iFluor® 546 Succinimidyl Ester (CAT#: WJY0-LS14337)
- Anti-CD4 MAb (Clone 29)-iFluor® 514 Succinimidyl Ester (CAT#: WJY0-LS11928)
- Anti-TNFSF13B MAb (Clone 9)-iFluor® 546 Succinimidyl Ester (CAT#: WJY0-LS15380)
- Anti-CD200 MAb (Clone 1)-iFluor® 555 Succinimidyl Ester (CAT#: WJY0-LS15544)
- Anti-C-kit MAb (Clone 9)-iFluor® 405 Succinimidyl Ester (CAT#: WJY0-LS2022)
- Anti-HLA-DRB1 MAb (Clone 1)-iFluor® 555 Succinimidyl Ester (CAT#: WJY0-LS15983)
- Icrucumab-Bodipy FL (CAT#: ADC-FL-1488)
- Anti-CD40 MAb (Clone 16)-iFluor® 450 Succinimidyl Ester (CAT#: WJY0-LS7338)
- Anti-TNFRSF17 MAb (Clone 1)-iFluor® 532 Succinimidyl Ester (CAT#: WJY0-LS12605)
Published Data
+ Submit Publications
Scientific Resources
Customer Reviews and FAQs
There are currently no Customer reviews or questions for ADC-FL-1411. Click the button above to contact us or submit your feedback about this product.
Quick Links
Other Products
Same Target
| CAT# | Product Name | Linker | Payload |
| ADC-W-2243 | Anti-ERBB3 (Duligotumab)-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
| ADC-W-2240 | Anti-ERBB3 (Duligotumab)-SMCC-DM1 ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine) |
| ADC-W-2366 | Anti-ERBB3 (Duligotuzumab)-SMCC-DM1 ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine) |
| ADC-W-2367 | Anti-ERBB3 (Duligotuzumab)-SPDB-DM4 ADC | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) |
| ADC-W-2371 | Anti-ERBB3 (Duligotuzumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
Online Inquiry
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.